-
Stemirna Therapeutics Halts mRNA Vaccine Factory Construction Amid Low Demand
•
China-based Stemirna Therapeutics Co., Ltd has decided to halt the construction of a factory intended for the manufacturing of its mRNA-based COVID-19 vaccine. This decision comes in response to an anticipated lack of sufficient market demand. According to a Reuters report, Stemirna had initiated testing production at the site but…
-
Alphamab Oncology Partners with Stemirna for BsAb and mRNA Vaccine Development
•
China-based Alphamab Oncology (HKG: 9966) has announced a strategic partnership with Shanghai-based mRNA drug developer Stemirna Therapeutics Co., Ltd. The collaboration focuses on the clinical development of bispecific antibodies (BsAbs) and mRNA vaccines, with an initial focus on the combination of KN052 and SWP1001. No financial details of the partnership…
